登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属华山医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06759233,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
WHO pathology type: adenocarcinoma, neuroendocrine tumor;
入选标准第 3 条
Patients diagnosed with advanced gastric cancer (stage IV in AJCC 8th edition staging, including locally progressive gastric cancer with unresectable factors (IVa) and gastric cancer with distant metastases (IVb); Bowman's staging type I, II, and III), who are unable to be surgically resected or do not tolerate surgical resection, and who have undergone progression after 1-2 lines of conventional chemotherapy;
入选标准第 1 条
ECOG score ≤2;
入选标准第 9 条
Important organ functions must be met: ① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula;
入选标准第 5 条
Blood routine: Hgb≥70g/L,ANC≥1.5×109/L,PLT≥80×109/L;
入选标准第 6 条
Pregnancy test must be negative in women of childbearing age;
入选标准第 8 条
Pregnant or breastfeeding women, or women with pregnancy plans within six months;
排除标准第 1 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06759233,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients diagnosed with advanced gastric cancer (stage IV in AJCC 8th edition staging, including locally progressive gastric cancer with unresectable factors (IVa) and gastric cancer with distant metastases (IVb); Bowman's staging type I, II, and III), who are unable to be surgically resected or do not tolerate surgical resection, and who have undergone progression after 1-2 lines of conventional chemotherapy; Age greater than 18 years and less than 80 years; WHO pathology type: adenocarcinoma, neuroendocrine tumor; Expected survival greater than 3 months and controllable distant metastases as judged by the physician; Important organ functions must be met: ① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula; Blood routine: Hgb≥70g/L,ANC≥1.5×109/L,PLT≥80×109/L; Coagulation function: PT and APPT <2 times the normal value; Pregnancy test must be negative in women of childbearing age; ECOG score ≤2; Signed informed consent.排除标准:Exclusion Criteria:
Pregnant or breastfeeding women, or women with pregnancy plans within six months; Infectious diseases (e.g. AIDS, syphilis, active tuberculosis); Patients with active hepatitis B or C infection; Combination of other primary malignant tumors; Patients who have participated in a clinical trial within one month; Patients taking antiplatelet or anticoagulant drugs within the last week; Patients with gastric cancer combined with active bleeding; Large amount of ascites (ascites ≥3000ml); Cardia obstruction or pyloric obstruction; patients with combined active infection or autoimmune disease; Those who the doctor thinks there are other reasons not to be included in the treatment.
引自 ClinicalTrials.gov, NCT06759233, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06759233,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。